using mrd status as a metric of car-t efficacy in patients with multiple myeloma
Published 1 year ago • 104 plays • Length 3:53Download video MP4
Download video MP3
Similar videos
-
1:15
prognostic value of early bone marrow mrd status in car-t therapy for multiple myeloma
-
1:59
methods used to assess mrd status in multiple myeloma
-
2:48
mrd status by mass spectrometry with easym predicts outcomes following autosct in multiple myeloma
-
1:36
the importance of mrd as a prognostic tool in multiple myeloma
-
4:21
mrd as a monitoring technique of allosct and car-t in aml/all
-
1:50
the possibility of using mrd status to drive treatment in aml
-
1:20
mrd in myeloma
-
1:13
molecular mrd as a prognostic marker for aml patients with mutated cebpa
-
10:52
what are some possible uses of mrd testing?
-
8:59
how to read an mri of the brain | first look mri
-
4:22
arcellx employee testimonial video | shot by lnj designs
-
0:59
phase i study of cart-ddbcma in r/r multiple myeloma
-
2:55
using mrd to guide treatment decisions during sct in multiple myeloma
-
1:09
using mrd and pet/ct to assess responses post-asct in myeloma
-
2:00
advancing mrd monitoring in myeloma
-
5:00
meta-analysis: anti-bcma car-t in r/r multiple myeloma
-
2:31
determining the optimal threshold to test mrd in multiple myeloma
-
2:11
mrd as a predictor of risk in myeloma
-
1:55
mrd monitoring for myeloma
-
3:47
using mrd to analyze the benefit of autologous sct in patients with myeloma
-
3:18
phase i study of cart-ddbcma in r/r multiple myeloma
-
2:17
the benefit of detecting minimal residual disease in mm